References
- Damewood M. D., Shen W., Zacur H. A., Schlaff W. D., Rock J. A., Wallach E. E. Disappearance of exogenously administered human chorionic gonadotropin. Fertil. Steril. 1989; 52: 398–400
- Tan S. L. Simplifying in‐vitro fertilization therapy. CIRRR. Opin. Obstet. Gynecol. 1994; 6: 111–14
- Saal W., Glowania H. J., Hengst W., Happ J. Pharmacodynamics and pharmacokinetics after subcutaneous and intramuscular injection of human choronic gonadotropin. Fertil. Steril. 1991; 56: 225–9
- Saal W., Happ J., Cordes U., Glowania H. J., Baum R., Schmitt M. Subcutaneous gonadotropin therapy in male patients with hypogonadotropic hypogonadism. Fertil. Steril. 1991; 56: 319–24
- Araujo E., Jr, Bernardini L., Frederick J. L., Asch R. H., Balmaceda J. P. Prospective randomized comparison of human chorionic gonadotropin versus intramuscular progesterone for luteal‐phase support in assisted reproduction. J. Assist. Reprod. Genet. 1994; 11: 74–8
- Thompson K. A., LaPolt P. S., Rivier J., Henderson G., Dahl K. D., Meldrum D. R. Gonadotropin requirements of the developing follicle. Fed. Steril. 1995; 63: 273–6
- Wikland M., Borg J., Forsberg A. S., Jakobsson A. H., Svalander P., Waldenstrom U. Human chorionic gonadotropin self‐administered by the subcutaneous route to induce oocyte maturation in an in‐vitro fertilization and embryo transfer programme. Hum. Reprod. 1995; 10: 1667–70
- Braunstein G. D., Bloch S. K., Rasor J., Winikoff J. Characterization of antihuman chorionic gonadotropin serum antibody appearing after ovulation induction. J. Clin. Endocrinol. Metab. 1983; 57: 1164–7
- Nader S., Berkowitz A. S. Study of the pharmacokinetics of human chorionic gonadotropin and its relation to ovulation. J. In Vitro Fert. Embryo Transf 1990; 7: 114–18